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Abstract
Pathogenic mutations in APP, PSEN1, PSEN2, MAPT and GRN have previously been linked to familial early onset forms of
dementia. Mutation screening in these genes has been performed in either very small series or in single families with late
onset AD (LOAD). Similarly, studies in single families have reported mutations in MAPT and GRN associated with clinical AD
but no systematic screen of a large dataset has been performed to determine how frequently this occurs. We report
sequence data for 439 probands from late-onset AD families with a history of four or more affected individuals. Sixty
sequenced individuals (13.7%) carried a novel or pathogenic mutation. Eight pathogenic variants, (one each in APP and
MAPT, two in PSEN1 and four in GRN) three of which are novel, were found in 14 samples. Thirteen additional variants,
present in 23 families, did not segregate with disease, but the frequency of these variants is higher in AD cases than
controls, indicating that these variants may also modify risk for disease. The frequency of rare variants in these genes in this
series is significantly higher than in the 1,000 genome project (p=5.09610
25; OR=2.21; 95%CI=1.49–3.28) or an
unselected population of 12,481 samples (p=6.82610
25; OR=2.19; 95%CI=1.347–3.26). Rare coding variants in APP, PSEN1
and PSEN2, increase risk for or cause late onset AD. The presence of variants in these genes in LOAD and early-onset AD
demonstrates that factors other than the mutation can impact the age at onset and penetrance of at least some variants
associated with AD. MAPT and GRN mutations can be found in clinical series of AD most likely due to misdiagnosis. This
study clearly demonstrates that rare variants in these genes could explain an important proportion of genetic heritability of
AD, which is not detected by GWAS.
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Introduction
Mutations in amyloid-beta precursor protein (APP), presenilin 1 and 2
(PSEN1, PSEN2) are known to cause early onset (,60 years)
familial Alzheimer disease (AD) [1–5]. While initially considered to
solely cause early onset AD (EOAD), mutations in PSEN1 and
PSEN2 have been reported in several families with both late and
early onset disease [6–10]. Screening for mutations in PSEN1 has
been performed mainly in early-onset families, although a small
number of families including late onset (.60 years) cases (,100
families) were also screened [2,6–8,11–14]. Similarly, mutation
screening efforts in APP, which have historically been limited to
exons 16 and 17, have focused on early onset families but have
included some late onset families [11,15–17]. Screening of 40 late-
onset AD (LOAD) families for APP mutations in the exons 16–17
identified a pathogenic APP mutation (Glu693Gly) with incom-
plete penetrance in a single family [17]. Mutations in progranulin
(GRN) and in microtubule associated protein tau (MAPT) are an
established cause of familial frontotemporal dementia (FTD)
[18,19]. Some individuals carrying these mutations have been
reported with clinical manifestations indistinguishable from AD
[20–28], but the frequency of mutations in GRN and MAPT in
clinical series of LOAD cases is unknown. The identification of
mutations in these genes in cases with clinically diagnosed AD
would change not only the diagnosis and treatment but create the
need for genetic counseling.
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31039While there has been considerable success in the identification
of genes contributing to EOAD, LOAD is far more frequent,
accounting for 99% of all AD cases. LOAD remains a less well
understood disorder. The major genetic risk factor for LOAD is
APOE genotype [29]. The frequency of mutations in APP, PSEN1,
PSEN2 in LOAD families is unknown because no study has
systematically screened these genes in a large series of LOAD
families. Because LOAD is so much more common than EOAD,
the presence of even a low frequency of mutations would represent
a large number of affected families.
Alzheimer Disease is a complex disease and shows heritability of
up to 80% [30]. Most recent genetic studies of AD have focused on
the identification of common variants associated with risk for AD
through genome-wide association studies (GWAS). These studies
have identified several new genes that show significant association
after multiple test correction in multiple datasets: CLU, PICALM,
BIN1, CR1, ABCA7, MS4A6A, CD33 and CD2AP [31–35].
However, each of these new signals only account for about 4–
9% of the variance in AD susceptibility [36]. The total proportion
of heritability explained by the genes that show an association with
AD (including APOE) is estimated to be 23% [37], therefore a
large proportion of the heritability for LOAD remains unex-
plained.
GWAS studies are only able to identify common variants that
are associated with disease. Importantly, the effect of rare variants
cannot be determined in these studies. It has been suggested that
the combined effect of rare deleterious mutations could explain a
substantial fraction of genetic susceptibility to many common
diseases [38–43]. Rare alleles can only be identified through
resequencing large populations.
In this study we have screened a large collection of LOAD
families for mutations in APP, PSEN1, PSEN2, MAPT and GRN.
We used a method that combines a pooled-DNA approach with
next-generation sequencing technology and bioinformatics analy-
ses [44,45] to identify rare and novel variants in these genes in 439
families with a history of LOAD and/or dementia in four or more
family members (Table 1 and 2). This study allows us to accurately
estimate the mutation frequency in these genes in LOAD and the
effect of rare variants with risk for disease.
Results
We identified 33 nonsense, missense and splice-site sequence
variants in 60/439 (13.7%) individuals, including five known
pathogenic variants in ten individuals (2.3%), and three novel
potentially pathogenic alleles in four individuals (0.9%). An
additional variant in GRN, reported previously to be non-
pathogenic, because it was present in a very small number of
unaffected samples, segregated perfectly with disease status, was
not present in 2,692 control chromosomes and may be pathogenic.
The fact that it was present in control individuals in previous
studies may be because of incomplete penetrance. Pathogenic or
likely-pathogenic variants were found in all genes except PSEN2
(Table 3). The frequency of rare variants in APP, PSEN1 and
PSEN2 in this dataset was significantly higher than the frequency
of rare variants found in these genes in three series not enriched
for AD cases (GlaxoSmithKline study (GSK study), 1,000 genome
project and Exome Variant Server). In the GlaxoSmithKline study
(see Materials and Methods and Supporting Materials and
Methods S1; n=12,481), a total of 376 novel and rare non-
synonymous, variants were found in APP, PSEN1 and PSEN2
(2.91% of the samples), but we found 28 rare non-synonymous
variants (6.38%) in our 439 samples (p=6.82610
25; OR=2.19;
95%CI=1.347–3.26). In the 1,000 genomes project only 25 rare
(MAF,0.05) non-synonymous, nonsense or splice-site variants
were identified in these genes from three different populations
(CEU, YRI and CHBJPT; (p=5.09610
25; OR=2.21;
95%CI=1.49–3.28; see Supporting Materials and Methods S1).
The Exome Variant Server (http://evs.gs.washington.edu/EVS/)
[46], is a database with exome sequencing data for 1,326
European-American and 1,067 African-American selected for
heart, lung and blood disorders. In this database there were
reported 198 novel and rare non-synonymous, nonsense or splice-
site variants in these 2,393 individuals, which is statistically lower
Table 1. Distribution of the families by the number of
affected individuals in each family.
# affected # families % # sequence variants %
28 1 0.23 1 1.67
20 2 0.46 2 3.33
19 1 0.23 0 0.00
17 1 0.23 2 3.33
16 1 0.23 0 0.00
15 1 0.23 0 0.00
14 1 0.23 0 0.00
13 5 1.14 1 1.67
12 3 0.68 0 0.00
11 4 0.91 0 0.00
10 13 2.96 2 3.33
9 14 3.19 2 3.33
8 27 6.15 5 8.33
7 32 7.29 6 10.00
6 54 12.30 5 8.33
5 107 24.37 9 15.00
4 172 39.18 25 41.67
TOTAL 439 60
The number of families with different numbers of affected individuals is shown.
More than 50% of the families have 4 or 5 affected individuals. The number of
sequence variants found in each group is also shown.
doi:10.1371/journal.pone.0031039.t001
Table 2. Demographic data for the cohort.
AAO (years) Sequenced sample 69.9268.37
(range 30–92)
Families (mean age at onset) 72.8065.62
(range 60–89)
Ethnicity European ancestry 76.5%
White- Hispanics 14.6%
Black- Hispanics 2.7%
African-American 2.7%
others 3.6%
Diagnosis Definite AD 26.94%
Probable AD 71.46%
Possible AD 1.59%
The mean, the standard deviation and the range for the age at onset (AAO) for
the sequenced samples and the families are shown. For the families the AAO
represents the mean AAO of the affected individuals of each family.
doi:10.1371/journal.pone.0031039.t002
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24; OR=1.79; 95%CI=1.31–
2.43). These results most likely reflect the increased recurrence risk
among densely affected LOAD families. It is possible therefore
that some of these new variants could be pathogenic or disease
modifiers.
Pathogenic or likely pathogenic mutations
We identified eight sequence variants, one each in APP and
MAPT, two in PSEN1, and four in GRN, in a total of 14 families
(3.2% of the total families) that are known to cause disease or
appear to be highly penetrant rare pathogenic alleles, based on
segregation data, bioinformatics and sequence data in additional
controls. Three of these variants are novel and five were previously
reported (Table 4, 5 and Table S2). The sequence variants
showing perfect segregation were the previously reported patho-
genic G206A mutation in PSEN1 [2,4], the previously reported
pathogenic variant GRN R110X [18,47] and GRN G515A. In each
family, all of the genotyped affected individuals carried the
sequence variants, but none of the unaffected individuals were
carriers. PSEN1 G206A and GRN R110X were not found in 1,806
AD cases and 1,346 unrelated controls. GRN G515A was found in
an additional AD case of European-descent (from the 1,806
screened) but not in the 1,346 unrelated controls.
The PSEN1 A79V mutation was found in four of the 439
sequenced samples (Table 3 and 4), including the most densely
affected family with 28 affected individuals (Table 1). The mutation
in this family was reported previously by sequencing samples with
extreme cerebrospinal fluid Ab levels [6]. The sequenced individual
from this family had autopsy confirmed AD and an AAO of 76
years, which was similar to the mean AAO in the entire family.
Although A79V is a known pathogenic mutation, seen in families
with early onset AD [1,2], the mutation did not show perfect
segregation with disease in this family (Figure 1A). One of the four
genotyped affected individuals (AAO 77 years) did not carry the
mutation, possibly representing a phenocopy. In addition, three
unaffected individuals carried the mutation but their mean age at
last assessment was more than ten years below the mean onset of
disease in the family. These individuals are likely presymptomatic.
PSEN1 A79V was found also in a sporadic AD case (from the 1,806
screened), but not in the 1,346 unrelated controls.
For the novel variants APP N660Y (exon 16) and MAPT G201S
(exon 9), some of the carriers were asymptomatic at the time of the
last assessment (Table 4), but in all cases, the age at last assessment
of the unaffected carriers is lower than the oldest age at onset for
the affected carriers. Both APP N660Y, and MAPT G201S are
predicted to be damaging by Polyphen2 [48]. The APP N660Y
variant was not found in 1,806 AD cases, 1,346 unrelated controls,
nor in the 12,481 subjects not enriched for AD (GSK study), nor in
the Exome Variant Server. The MAPT G201S variant was found
in an additional case from the NIA-LOAD study (from the 847
screened). The MAPT G201S variant was present in the affected
sibling but not in an unaffected family member. This variant was
not found in 1,346 unrelated elderly non-demented controls
(Table 5), nor in the Exome Variant Server.
An additional known pathogenic mutation, R493X, and a novel
potentially pathogenic variant, c.1414-1G.T, were identified in
GRN. However as with the PSEN1 A79V mutation, these GRN
variants do not show perfect segregation (Table 4, Figure 1B). The
R493X mutation was present in a single demented individual
(AAO=70), but was absent in another three demented individuals
(AAO=78.361.15), suggesting that these non-carriers are pheno-
copies. Four young unaffected individuals are also mutation
carriers. The R493X has been found in more than 12 FTD
kindreds (AD&FTD mutation database) and functional data has
shown that the mutation results in a premature termination codon
causing nonsense-mediated mRNA decay [18,19]. In the families
with the GRN c.1414-1G.T variant we also found a single affected
individual who did not carry the sequence variant. The age at onset
of this individual is higher than the mean onset for the affected
individuals carrying the sequence variant, suggesting that this
individualmaybe a phenocopy.The GRN splice-site variant c.1414-
1G.T affects the last nucleotide of intron 10 within a core splice-
site. This variant was found in two Hispanic families, one of which
had 20 affected individuals. This variant is predicted to alter an
acceptor splice-site (NetGene2 Prediction score for the wild type
variant 1.00vs. 0.00 for the mutant) causing exon skipping.A recent
screen for GRN pathogenic mutations identified a similar variant
(c.1414-2A.G) affecting the same core splice-site. Ex vivo splicing
assays confirmed that the mutation c.1414-2A.G affects splicing of
the exon [47]. Neither the GRN R493X nor the c.1414-1G.T
variant were found in the controls or in the sporadic AD cases
(Table 5), nor the Exome Variant Server. None of the sequenced
individuals with pathogenic or likely pathogenic mutations in GRN
or MAPT had neuropathologic confirmation of diagnosis. These
individuals most likely have frontotemporal dementia that has a
clinical presentation indistinguishable from AD.
Table 3. Number of rare non-synonymous and splice-site variants found in the 439 sequenced samples.
Previously reported New**
Pathogenic* Path. Unkown* Not Path.* Likely Pathogenic* Path. Unkown* Not Path.* total
#mut #fam #mut #fam #mut #fam #mut #fam #mut #fam #mut #fam #mut #fam
A P P 0000 1111 2 22367
P S E N 1 2700 0000 1 10038
P S E N 2 0031 30000 0 00031 3
MAPT 0011 0011 1 141 2 71 5
G R N3311 4412 3 4231 4 1 7
total 5 10 5 15 5 5 3 4 7 8 8 18 33 60
2.3% 3.4% 1.1% 0.9% 1.8% 4.1% 13.7%
*Based on our segregation analyses.
**Not present in the AD&FTD mutation database or in dbSNP.
Only the rare (MAF,0.05) non-synonymous, splice-site and nonsense sequence variants are shown.
doi:10.1371/journal.pone.0031039.t003
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carriers among non-demented controls, and our bioinformatic
analyses strongly suggest that APP N660Y, MAPT G201S and
GRN c.1414-1G.T are rare pathogenic alleles exhibiting high
disease penetrance.
Non-pathogenic or likely non-pathogenic variants
We identified a total of thirteen (eight novel) sequence variants
(23 families) which clearly did not segregate with disease and/or
were found in controls suggesting that these variants are not
causative mutations (Table 5 and Table S2), but our analyses
suggest that some of them may be disease modifiers. Some of these
variants (PSEN2 R71W and M174V, and MAPT R5H) were
previously classified as pathogenic in the AD&FTD mutation
database; however our results do not support this designation.
These variants occurred in multiple families but did not segregate
with disease status in any family (Table S2) and were observed
multiple times in the unselected samples and the elderly non-
demented controls samples (Table 5).
The majority of the genetic variants identified in these genes, so
far, have been classified as pathogenic or non-pathogenic, but rare
variants in these genes could also be risk factors for disease. Carriers
of the R62H and R71W PSEN2 variants have a significantly earlier
age at onset than affected non-carriers even after correcting for
APOE genotype (R71W: 70.2 vs 76.7, p=0.0005; R62H: 71 vs 75
years, p=0.0019; Table S3), suggesting that these variants could be
disease modifiers.
The novel variant APP G322A was present in four affected
individuals but absent in 7 additional affected members from the
same family and therefore does not segregate with disease. This
variant was not found in 12,481 samples unselected for AD
(P=1.0610
27). The bioinformatic analyses predict it as probably
damaging. These data suggest that the APP G322A variant may be a
risk factor for AD, but more studies will be necessary to confirm this
hypothesis.
The frequency of these variants is, in most cases, higher in AD
cases than in controls. As these variants have very low frequency,
the power to identify significant differences in cases vs. controls is
very limited. However, if we combine all of the novel variants
classified as non-pathogenic (Table 5), the frequency of these
variants in AD cases is significantly higher than in controls (5.66%
in AD cases vs 2.89% in controls; p=3.11610
24; OR=1.86;
95%CI=1.30–2.65), suggesting that these variants may increase
risk for AD, although they are not causative. See Supporting
Results S1 for full results about the likely non-pathogenic variants
unknown pathogenicity.
Variants with unknown pathogenicity
For eight novel variants (APP G191E and V340M; PSEN1 P7L;
GRN D135V, M207T, V514M, V519M; and MAPT S427F),
segregation within families was inconclusive, in part due to the small
number of family members sampled. The APP and PSEN1 variants
were absent from the 12,481 unselected samples, and the GRN
D135V and V514M and MAPT mutation were not found in 1,346
non-demented elderly controls (Table 5). Bioinformatics analyses
predict that the APP, MAPT, and GRN V519M variants areprobably
damaging (Table S2). The total number of variants in AD cases is
significantly higher than in controls (2.23% in AD cases vs 0.52% in
controls;p=9.46610
212;OR=4.38;95%CI=1.65–11.57)strong-
ly suggesting that some of these novel variants maycause orincrease
risk for AD.
Table 4. List of the pathogenic and likely pathogenic non-synonymous, splice site and nonsense sequence variants identified.
Gene Change
# of
fam Status
Polyphen2
prediction Affected Unaffected
Carriers Non-carriers Carriers Non-carriers
Pathogenic or likely pathogenic
APP N660Y 1 Novel probably damaging 3 0 1 1
61.663 - 62 69
PSEN1 A79V 4 Previously reported Pathogenic probably damaging 10 1 3 13
68.968.5 77 6064.3 70.62612.95
G206A 3 Previously reported Pathogenic probably damaging 6 0 0 1
60.866.7 - - 40
MAPT G201S 1 Novel probably damaging 2 0 2 2
7460- 6 1 65.7 4964.2
GRN R110X 1 Previously reported Pathogenic probably damaging 3 0 0- 5
66.362.1 - - 72.265.26
c.1414-1G.T 2 Novel probably damaging 8 1 0 1
65.8611.7 74 - 70
R493X 1 Previously reported Pathogenic probably damaging 1 3 4 3
70 78.361.15 56.364.04 56.3611.06
G515A 1 Previously reported Not pathogenic probably damaging 3 0 0 1
8067.5 - - 66
List of the non-synonymous, splice and nonsense variants identified in the 439 sequenced samples. The identified variants were genotyped in all the available family
samples. The number of affected carriers, non-carriers and the un-affected carriers, non-carriers, as well as the mean age at onset and the standard deviation for the
affected and the age at last assessment for the unaffected individuals are shown.
The variants were classified as pathogenic, or likely pathogenic based on our segregation analyses, bioinformatic analyses, sequencing and genotyping data in
additional cases and controls (table 5) and previous reports.
doi:10.1371/journal.pone.0031039.t004
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APOE is the strongest known genetic risk factor for sporadic and
familial LOAD. Therefore we analyzed the effect of APOE in these
families. We initially compared the APOE4 allele frequency in the
sequenced samples comparing carriers for rare sequence variants
against the non-carriers. There was no significant difference
between these two groups (71.15% vs 72.29% p=0.86). However
we found that the APOE4 allele frequency in these families is
significantly higher compared to sporadic AD cases (72.13% vs.
60%, p=2.18610
26, OR=1.71, 95%CI: 1.36–2.17) and controls
(72.13% vs. 26%, p=5.28610
285; OR=7.37, 95%CI: 5.86–
9.27)(APOE4 frequencies obtained from Alzgene). These results
confirm that APOE is a strong genetic risk factor in these families,
and suggest that the APOE4 genotype could be sufficient to cause
disease in some of these families, as suggested in a recent report
[49]. However, we found likely causative variants in individuals
with every APOE genotype and no difference in the APOE4
frequency among the samples with and without rare sequence
variants. As reported previously, we found that APOE4 is
associated with a dose dependent decrease in the AAO (Table
S3 and Figure S1). APOE4 carriers with a rare sequence variant in
the screened genes have a lower AAO than APOE4 carriers
without a rare sequence variant in these genes (67.3 y vs. 69.8 y;
p=0.025), suggesting that these sequence variants modify AAO of
AD independently of APOE genotype.
Comparison of the individuals and families with and
without sequence variants
The age at onset of individuals with rare non-synonymous
variants in these genes was significantly lower than that for
sequenced individuals with normal gene sequence (67.8 years vs
70.5 years p=0.004), but there was no difference in the mean age
at onset in families with rare non-synonymous variants compared
to those without sequenced variants (Table S4). The major feature
Table 5. Allele frequency of all variants in the initial dataset and in additional case-control series.
familial cases AD cases Controls+unselected
Likely pathogenic Ethnicity Counts % Counts % Counts %
APP N660Y European 1/439 0.228 0/1,806 0.000 0/(1,346+12,481) 0.000
MAPT G201S European 1/439 0.228 1/1,806 0.055 0/1,346 0.000
GRN c.1414-1G.T Hispanics 2/439 0.456 0/1,806 0.000 0/1,346 0.000
G515A Hispanics 1/439 0.228 1/1,806 0.055 0/1,346 0.000
Likely non-pathogenic
APP G322A Hispanics 1/439 0.228 0/1,806 0.000 0/1,346 0.000
E599K European 2/439 0.456 2/1,806 0.111 2/1,346 0.148
A673T European 1/439 0.228 0/1,806 0.000 0/1,346 0.000
PSEN2 R62H Mixed 6/439 1.367 18/1,806 0.997 13/1,346 0.965
R71W European 6/439 1.367 26/1,806 1.439 3/1,346 0.222
M174V European 1/439 0.228 3/1,806 0.166 0/1,346 0.000
MAPT R5H European 1/439 0.228 1/1,806 0.055 0/1,346 0.000
R168C European 1/439 0.228 3/1,806 0.166 0/1,346 0.000
A152T European 5/439 1.140 17/1,806 0.941 6/1,346 0.445
V224G European 2/439 0.456 10/1806 0.553 12/1,346 0.891
A239T European 4/439 0.911 4/1,806 0.221 4/1,346 0.297
GRN P85A European 2/439 0.456 0/1,806 0.000 0/1,346 0.000
V141I European 1/439 0.228 0/1,806 0.000 0/1,346 0.000
T268M European 1/439 0.228 1/1,806 0.055 0/1,346 0.000
A324T European 1/439 0.228 5/1,806 0.277 2/1,346 0.148
D376N European 1/439 0.228 0/1,806 0.000 0/1,346 0.000
R433Q European 1/439 0.228 0/1,806 0.000 0/1,346 0.000
Unknown
APP G191E European 1/439 0.228 0/1,806 0.000 0/(1,346+12,481) 0.000
V340M Hispanics 1/439 0.228 0/1,806 0.000 0/(1,346+12,481) 0.000
PSEN1 P7L European 1/439 0.228 0/1,806 0.000 0/1,346 0.000
MAPT S427F Hispanics 1/439 0.228 0/1,806 0.000 0/1,346 0.000
GRN D135V Hispanics 1/439 0.228 0/1,806 0.000 0/1,346 0.000
M207T European 1/439 0.228 0/1,806 0.000 0/1,346 0.000
V514M European 1/439 0.228 0/1,806 0.000 0/1,346 0.000
V519M Hispanics 2/439 0.456 2/1,806 0.110 7/1,346 0.520
The novel variants that were classified as likely pathogenic or unknown were genotyped in an additional 1,806 unrelated AD cases and 1,346 controls. Among the 1,346
controls 113 are of Hispanic origin. The GSK dataset (n=12,481, were also used to analyze the presence of some variants in APP, PSEN1 and PSEN2).
doi:10.1371/journal.pone.0031039.t005
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normal gene sequence was the reported number of affected
individuals per family. We found that the families with rare
sequence variants had significantly more affected individuals than
families without sequence variants (average=6.88 vs 5.62;
p=0.0008; Figures S2, S3, S4, Table S4).
Discussion
Pathogenic mutations in APP, PSEN1, PSEN2, MAPT and GRN
have previously been linked to familial early onset forms of
dementia. A recent report looking at common variants in APP,
PSEN1, PSEN2 and MAPT in a large case-control sample
consisting of 3,940 cases and 13,373 controls, found that common
variants in these genes are unlikely to make strong contributions to
susceptibility for LOAD [50]. However, the impact of rare
variants in these genes in late onset clinically diagnosed AD
remains unclear. This is the first study to systematically screen for
rare variants and pathogenic mutations in APP, PSEN1, PSEN2,
MAPT and GRN in a large clinical series of well-characterized
families densely affected by LOAD.
We found seven families carrying two known causative
mutations in PSEN1 (A79V and G206A [1–4]), and three families
carrying two clearly causative mutations in GRN (R110X, R493X
[19,22,47,51–54]. In some families these causative mutations
(PSEN1-A79V, and GRN-R493X, Figure 1) did not completely
segregate with disease, illustrating how phenocopies, potential
presymptomatic individuals and reduced penetrance may compli-
cate the interpretation of novel sequence variants in familial and
sporadic LOAD. While we can identify the phenocopies in families
Figure 1. Pedigrees for some of the sequenced families illustrating the presence of phenocopies and low penetrance mutations or
the presence of presymptomatic cases. A) Pedigree for a family with the PSEN1 A79V mutation. B) Pedigree for a family with the GRN R493X
mutation. AO indicates the subject or family report of age of onset of symptoms. AE=the age of last evaluation. MCI: Mild cognitive impairment or
questionable dementia by family report.+symbol indicates that the subject is positive for the indicated mutation.2symbol indicates that the subject
is negative for the indicated mutation. A number inside of a diamond indicates the number of subjects with the same status. Fully shaded circles or
squares indicate confirmed AD by autopsy. Three/fourths shaded symbol indicates probable AD diagnosed using NINCDS-ADRDA criteria. One/fourth
shaded symbol indicates that the family reports this individual has AD.
doi:10.1371/journal.pone.0031039.g001
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R110X (Fig. 1), it is more challenging in families with novel
variants, because phenocopies might be interpreted as a failure of
the variant to segregate with disease. Putative pathogenic variants
in genes that cause late onset rather than early onset dementia
could have a less severe effect on protein function due to other
genetic or environmental modifiers that are not present when
these same variants result in early onset disease. This would lead to
the occurrence of reduced penetrance. Indeed, several cases of
reduced penetrance have been reported in families with PSEN1
and GRN mutations [51,55–58]. Despite these problems in our
segregation data, the absence of these variants in a large non-
demented control series and the bioinformatics analyses suggest
that the novel variants APP N660Y, GRN c.1414-1G.T and
MAPT G201S are likely to be causative mutations or highly
penetrant rare disease alleles.
In total 14 (3.2%) of the 439 sequenced samples from densely
affected families carried a causative or likely-causative mutation.
Although this percentage is low, the overall number of LOAD
cases carrying mutations in these genes is likely to be higher than
the number of early onset cases, because LOAD is much more
frequent. Approximately 10–20% of all patients with LOAD have
a family history of dementia. Of those, approximately 10% have a
history of four or more affected family members. Based on our
analysis, we estimate 3.2% of these densely affected families would
have a causative mutation. Thus, 0.029–0.057% of all patients
with LOAD may carry a pathogenic mutation in these genes,
representing a minimum of 1,917–3,833 cases in the United
States.
It is likely that we have underestimated the actual number of
cases with causative mutations. First, the recurrence risk in family
members peaks with an age-at-onset of 85 years in the proband
[59,60]. Several families with more than 10 affected individuals
have no mutations in the genes studied here. Thus it is very likely
that there are novel AD causative genes yet to be discovered.
Second, some of the variants with unknown pathogenicity
reported in this study, such as, APP G220E and V340M, and
MAPT S427F, could be pathogenic, or risk factors. The scarcity of
available DNA samples from other family members with LOAD
made it difficult to determine whether or not these novel variants
segregate with disease. However, we did not find these variants in
additional controls and the bioinformatic analyses suggest that
these variants may be pathogenic. To confirm this hypothesis
more genetic and functional analyses will be necessary. Lastly,
some of the variants we found in this study (APP A79V, MAPT
G201V and GRN G515A) were also found in sporadic cases, but
not in controls. These results indicate that novel mutations remain
to be discovered and that mutations in these genes are also present
in LOAD cases with no clear family history. Together these results
suggest that any individual with a family history of dementia
affecting a large number of relatives and with an onset in the mid-
60s should be considered for mutation screening not only of the
AD genes (APP, PSEN1 and 2), but also MAPT and GRN. Our
study also indicates that mutations in these genes can be present in
1 to 3% of the sporadic cases. These cases may be classified as
sporadic because the family size is small, because of the lack of
medical records for other family members or because the variant
has low penetrance.
Another important finding is the observation of clinically
diagnosed AD families carrying previously reported and likely
novel pathogenic mutations in GRN and MAPT. Mutations in
these genes are typically associated with frontotemporal lobar
degeneration [18,19], but have been previously reported in
clinically diagnosed AD cases [20–28]. Our results show that
mutations in GRN and MAPT in a clinical series of LOAD families
are as common as mutations in the AD genes (APP, PSEN1 and 2).
Six families (1.37%) with pathogenic or likely pathogenic
mutations in GRN and MAPT were found vs. eight families
(1.82%) with mutations in APP and PSEN1. None of the
individuals with MAPT or GRN mutations had autopsy confirma-
tion of the clinical diagnosis. It is most likely that these individuals
have been misdiagnosed and that neuropathological diagnosis for
these individuals will be FTD and not AD.
Our study indicates that families carrying mutations in GRN or
MAPT can present with disease that is clinically indistinguishable
from probable AD even in specialist memory disorder clinics,
which is analogous to the observations that ‘‘AD mutations’’ can
present with frontotemporal lobar degeneration [61–63]. Identi-
fication of families and individuals carrying mutations in genes
associated with frontotemporal lobar degeneration will be
important for clinical management of these patients, particularly
as therapies are developed that target the specific pathophysiologic
processes of these disorders.
Some of the rare variants discovered in this study appear to
increase the risk for AD or modify the age at onset. We found a
very significant association of PSEN2 R62H and R71W with age at
onset. It is very likely that some of the variants classified as non-
pathogenic also increase risk for AD: When the individuals with
variants classified as pathogenic are removed (n=14), and the
frequency of rare non-synonymous variants is compared with
1,000 genome project data (p=1.93610
23; OR=2.18, 95%CI:
1.31–3.62), the GSK dataset (p=5.99610
23; OR=1.89, 95%CI:
1.19–3.00) or the Exome Variant Server (p=0.010; OR=1.48;
95%CI=1.06–2.06), there is still a significant excess of rare
variants in these genes in the LOAD cases. In the three datasets
(GSK 1,000 genome project, and Exome Variant Server) a large
proportion of samples are of non-European origin, therefore some
of the variants found in these datasets may represent population
specific alleles, decreasing the power of our analyses. If we focus on
the specific variants found in this study and compare their
frequency in elderly non-demented individuals, we found that
these variants may have a big impact on AD risk. The eight
variants classified as ‘‘unknown pathogenicity’’ have a combined
OR=4.38 (95%CI=1.65–11.57), and the variants classified as
‘‘non-pathogenic’’ have a combined OR=1.86 (95%CI=1.30–
2.65). The common variants identified in the last GWAS for AD
had ORs ranging from 1.26 to 1.11, with a combined OR of 2.23.
Therefore an individual carrying a single rare variant in one of
these genes has a higher likelihood of developing AD than
individuals varying all of the risk alleles for the novel genes found
in the recent GWAS studies. This is the first large study looking at
the effect of rare variants in candidate genes in AD. Additional
large studies are needed to replicate these findings.
This work provides some general guidelines to identify
individuals and families that should be prioritized for genetic
counseling and mutation screening. Although we did not find clear
phenotypic differences between the families carrying missense,
splice-site or nonsense variants compared with the families without
novel variants, the number of reported affected individuals and the
presence of at least one affected individual with an early age at
onset were strong indicators of the presence of a pathogenic
variant. Given the significant overlap in clinical presentation,
individuals with a strong family history of AD should also be
screened for mutations in MAPT and GRN, genes typically
associated with frontotemporal lobar degeneration, when no
autopsy is available. In families with a history of four or more
affected individuals and with an onset in the mid-60s, genetic
testing may be considered for PSEN1-2, APP, GRN and MAPT.
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genetic counsellors.
Rare coding variants in APP, PSEN1 and PSEN2, increase risk
for or cause late onset AD. Dividing AD into late onset and early
onset is probably not useful from a mechanistic point of view
because mutations in APP, PSEN1 and PSEN2 can be found in early
onset and late onset AD. Similarly, APOE4 increases risk for AD in
both early and late onset AD. Clearly factors other than the
mutation can impact the age at onset and penetrance of at least
some variants causing AD. MAPT and GRN mutations can be
found in clinical series of AD most likely due to misdiagnosis.
Finding a mutation in these genes would change the clinical
diagnosis in a demented individual. This will be particularly
important when mechanism-based therapies become available
because this would change the treatment of these individuals.
Lastly, familial aggregation is more important than age at onset in
determining the likelihood of an individual carrying a disease-
causing variant.
Materials and Methods
Patients
The NIA-LOAD Family Study recruited 992 multiplex LOAD
families, with at least two living affected individuals, from
throughout the United States. A description of these samples has
been reported previously [64]. We selected for sequencing all
families (439) that met the following criteria: at least 4 family
members reported with a history of dementia consistent with
LOAD, and either at least two affected family members reporting
an age of onset of 65 years or older or an average age of onset in
the family of 60 years or older (Table 1). The youngest affected
family member with the most definitive diagnosis was selected for
sequencing. In some families the age at onset for the sequenced
sample was lower than 60 years, but the mean age at onset for the
entire family was equal to or greater than 60 years (Table 2). We
chose individuals with autopsy confirmed disease (26.9%) over
those with probable (71.4%) or possible (1.5%) disease (NINCDS-
ADRDA) [65]. Written consent was obtained from all participants,
and the study was approved by the local IRB committees.
DNA sequencing and genotyping
We used the next-generation, pooled-DNA method described
by Druley et al. [44], and Vallania et al. [45] to identify sequence
variants in APP, PSEN1, PSEN2, MAPT and GRN. A more detailed
description of this method is provided in the Supporting Materials
and Methods S1 and Table S1. All rare (minor allele frequen-
cy,5%) missense, nonsense, and splice-site sequence variants
identified in the pooled DNA experiment were confirmed and the
specific sample carrying the variant was identified by direct
genotyping using standard procedures for Sequenom, Taqman or
Kaspar. We genotyped the confirmed variants in all available
family members to determine whether the sequence variant
segregated with disease. Common variants and synonymous
variants were not followed up.
Bioinformatics
PolyPhen2 [48] and Net2Gene [66] were used to evaluate the
effect of non-synonymous and splice-site variants on protein
function and structure. The AD&FTD mutation database (http://
www.molgen.ua.ac.be/ADMutations/) was used to identify se-
quence variants found in previous studies of early onset familial
dementia and to determine whether or not they were considered to
be disease-causative variants. The sequencing data from the 1,000
genome project and the GlaxoSmithKline study (GSK study; see
below and supporting Materials and Methods S1 and Table S5)
were used to estimate the frequency of novel and rare (minor allele
frequency less than 5%) missense, nonsense and splice site variants
in samples unselected for studies of AD. For APP, PSEN1 and
PSEN2 we had access to sequence data from the GSK study for the
exons of these genes including variant counts and allele
frequencies for 12,481 individuals from 10 disease collections
and 2 population-based studies all unselected for AD. Average age
of exam for this sample was 51.7 years. This dataset included
10,967 Caucasians, 594 African-Americans, 566 South Asians, 84
Ashkenazi Jews, 29 Hispanics and 241 individuals of mixed
ethnicity (see supporting Materials and Methods S1).
Genotyping additional cases and controls
All variants classified as ‘‘likely pathogenic’’ or with an
‘‘unknown pathogenicity’’, and some ‘‘non-pathogenic’’ variants
were genotyped in 961 sporadic AD cases, 1,346 unrelated elderly
non-demented controls [34,35] and a single case from each of the
remaining NIA-LOAD families (n=847 with ,/=3 affected
individuals) [64].
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the Kaplan-Meier method and tested for significant differences,
using a proportional hazards model (proc PHREG, SAS). Family
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Pathogenic Mutations in Familial Late-Onset AD
PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e31039sequence variants identified in this study, even if they were
considered non-pathogenic.
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Figure S3 The number of affected individuals and the age at
onset of the sequenced individual, but not gender or APOE
genotype are associated with the presence of non-synonymous,
nonsense or splice-site variants in the APP, PSEN1, PSEN2, MAPT
or GRN genes. We used a logistic regression model to analyze the
association of the number of affected individuals, the age at onset
of the sequenced individual, gender and APOE genotype with the
presence of sequence variants. The Odds Ratio (OR) and the 95%
confidence interval were calculated. The risk of having a sequence
variant in these genes increase by 1.33 (95%: 1.105–1.69) for every
two affected individuals in the family. The risk of having a
sequence variant in these genes decreased by 0.807 (95%: 0.67–
0.96) for every five years increase in age at onset.
(DOC)
Figure S4 ROC curve for the logistic regression model including
the number of affected individuals in a family and age at onset for
the presence or absence of sequence variations in the APP, PSEN1,
PSEN2, MAPT or GRN genes. We used a logistic regression model
to generate a ROC curve including the variables that could predict
the presence of a sequence variant in this series. A stepwise
regression analyses was used to include the most significant
variables among: APOE genotype, gender, age at onset and the
number of affected individuals in each family. The logistic
regression identified age at onset (p=0.0008; Area under the
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(p=0.0001; Area under the Curve=0.5779) in the second step.
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